RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves

April 16, 2026 - 22:57

A recent focus on regulatory reform for peptide therapies within certain political platforms is drawing attention to the burgeoning market for these treatments. Telehealth providers, already major distributors of GLP-1 medications for weight loss, are positioned to be significant beneficiaries if access pathways are simplified.

Industry analysts highlight companies like Hims & Hers, which has rapidly evolved its business to meet soaring demand for weight management solutions. The company’s early investment in a vertically integrated model for compounded GLP-1 medications has established a substantial customer base. This foundation could prove critical for future expansion into broader peptide offerings.

The immediate commercial opportunity, however, hinges on a key regulatory milestone. The U.S. Food and Drug Administration is conducting a comprehensive review of compounding practices for certain peptides, with new guidelines expected by 2026. The outcome of this review will define the legal and operational landscape for telehealth companies in this space.

A favorable regulatory environment could transform peptides from a niche offering into a major, sustained revenue stream for accessible healthcare platforms. The convergence of consumer demand, corporate infrastructure, and potential policy support is creating a watched and potentially transformative moment for digital health and wellness.